Engene Holdings Common Etf Debt To Equity
| ENGN Etf | USD 7.68 0.01 0.13% |
enGene Holdings Common fundamentals help investors to digest information that contributes to EnGene Holdings' financial success or failures. It also enables traders to predict the movement of EnGene Etf. The fundamental analysis module provides a way to measure EnGene Holdings' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to EnGene Holdings etf.
EnGene |
enGene Holdings Common ETF Debt To Equity Analysis
EnGene Holdings' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, enGene Holdings Common has a Debt To Equity of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) family and about the same as Health Care (which currently averages 0.0) category. This indicator is about the same for all United States etfs average (which is currently at 0.0).
EnGene Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses EnGene Holdings' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of EnGene Holdings could also be used in its relative valuation, which is a method of valuing EnGene Holdings by comparing valuation metrics of similar companies.EnGene Holdings is currently under evaluation in debt to equity as compared to similar ETFs.
Fund Asset Allocation for EnGene Holdings
The fund consists of 97.03% investments in fixed income securities, with the rest of funds allocated in various types of exotic instruments.Asset allocation divides EnGene Holdings' investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
EnGene Fundamentals
| Return On Equity | -1.23 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 158.68 M | ||||
| Shares Outstanding | 50.98 M | ||||
| Shares Owned By Insiders | 13.61 % | ||||
| Shares Owned By Institutions | 83.23 % | ||||
| Number Of Shares Shorted | 797.34 K | ||||
| Price To Book | 1.70 X | ||||
| EBITDA | (94.77 M) | ||||
| Net Income | (99.92 M) | ||||
| Total Debt | 9.78 M | ||||
| Book Value Per Share | 5.21 X | ||||
| Cash Flow From Operations | (24.74 M) | ||||
| Short Ratio | 3.74 X | ||||
| Earnings Per Share | (2.79) X | ||||
| Target Price | 28.86 | ||||
| Number Of Employees | 31 | ||||
| Beta | -0.76 | ||||
| Market Capitalization | 391.5 M | ||||
| Total Asset | 86.96 M | ||||
| Retained Earnings | (199.59 M) | ||||
| Working Capital | 80.18 M | ||||
| Year To Date Return | (0.98) % | ||||
| One Year Return | 4.07 % | ||||
| Three Year Return | 3.14 % | ||||
| Net Asset | 86.96 M | ||||
| Bond Positions Weight | 97.03 % |
About EnGene Holdings Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze enGene Holdings Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EnGene Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of enGene Holdings Common based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with EnGene Holdings
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if EnGene Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EnGene Holdings will appreciate offsetting losses from the drop in the long position's value.Moving against EnGene Etf
| 0.78 | VINC | Vincerx Pharma | PairCorr |
| 0.64 | ME | 23Andme Holding | PairCorr |
| 0.54 | DTIL | Precision BioSciences | PairCorr |
| 0.53 | A | Agilent Technologies Earnings Call Tomorrow | PairCorr |
| 0.47 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to EnGene Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace EnGene Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back EnGene Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling enGene Holdings Common to buy it.
The correlation of EnGene Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as EnGene Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if enGene Holdings Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for EnGene Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in EnGene Etf
EnGene Holdings financial ratios help investors to determine whether EnGene Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EnGene with respect to the benefits of owning EnGene Holdings security.